Westlake BioPartners Fund I, L.P. - Feb 12, 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
10%+ Owner
Signature
By: /s/ Jennifer L. Kercher, as Attorney-in-Fact
Stock symbol
KYTX
Transactions as of
Feb 12, 2024
Transactions value $
$0
Form type
4
Date filed
2/14/2024, 05:35 PM
Previous filing
Feb 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Conversion of derivative security +3.79M 3.79M Feb 12, 2024 See Footnote F1, F2
transaction KYTX Common Stock Conversion of derivative security +736K 736K Feb 12, 2024 See Footnote F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Series A-1 Redeemable Convertible Preferred Stock Conversion of derivative security $0 -4.4M -100% $0.00* 0 Feb 12, 2024 Common Stock 967K See Footnote F2, F4
transaction KYTX Series A-2 Redeemable Convertible Preferred Stock Conversion of derivative security $0 -8.83M -100% $0.00* 0 Feb 12, 2024 Common Stock 1.94M See Footnote F2, F4
transaction KYTX Series B Redeemable Convertible Preferred Stock Conversion of derivative security $0 -4.01M -100% $0.00* 0 Feb 12, 2024 Common Stock 880K See Footnote F2, F4
transaction KYTX Series B Redeemable Convertible Preferred Stock Conversion of derivative security $0 -3.35M -100% $0.00* 0 Feb 12, 2024 Common Stock 736K See Footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
F2 Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any.
F3 Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any.
F4 The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.